Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1991 Jul;85(1):80–84. doi: 10.1111/j.1365-2249.1991.tb05686.x

Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis.

Y Ikeda 1, G Toda 1, N Hashimoto 1, N Umeda 1, K Miyake 1, M Yamanaka 1, K Kurokowa 1
PMCID: PMC1535714  PMID: 1906385

Abstract

The occurrence of antibodies against recombinant human interferon-alpha 2a (IFN-alpha 2a) in patients with acute viral hepatitis (AVH) was examined by ELISA. Naturally occurring IgG anti-IFN-alpha 2a were found in 50% of patients with type A, 50% of those with type B and in 8.3% of those with non-A, non-B AVH. The corresponding frequencies of IgM antibodies were 80%, 30% and 33.3%, respectively. IgM anti-IFN-alpha 2a were found more frequently in patients with AVH type A than in normal control subjects (P less than 0.01). Anti-IFN-alpha 2a were detectable at the highest frequency 3 weeks after acute onset and then became negative. An absorption experiment revealed that IgM anti-IFN-alpha 2a did not cross-react with recombinant human IFN-alpha 2b. Immunoblotting analysis confirmed the binding of antibodies to IFN-alpha 2a. Sera positive for IgG and/or IgM anti-IFN-alpha 2a were unable to neutralize IFN-alpha 2a. The appearance of anti-IFN-alpha 2a was not correlated with disease severity. There was no evidence to suggest that anti-IFN-alpha 2a impaired the elimination of hepatitis virus. This is the first study to demonstrate the occurrence of anti-IFN-alpha 2a in patients with AVH. Detection of anti-IFN-alpha 2a may be useful for clarifying any underlying immune events in various diseases.

Full text

PDF
83

Images in this article

81Fig. 1
on p.81

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Caruso A., Bonfanti C., Colombrita D., De Francesco M., De Rango C., Foresti I., Gargiulo F., Gonzales R., Gribaudo G., Landolfo S. Natural antibodies to IFN-gamma in man and their increase during viral infection. J Immunol. 1990 Jan 15;144(2):685–690. [PubMed] [Google Scholar]
  2. Conlon K. C., Urba W. J., Smith J. W., 2nd, Steis R. G., Longo D. L., Clark J. W. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer. 1990 May 15;65(10):2237–2242. doi: 10.1002/1097-0142(19900515)65:10<2237::aid-cncr2820651013>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  3. Ikeda Y., Toda G., Hashimoto N., Aotsuka S., Yokohari R., Maruyama T., Oka H. Anticalmodulin autoantibody in liver diseases: a new antibody against a cytoskeleton-related protein. Hepatology. 1987 Mar-Apr;7(2):285–293. doi: 10.1002/hep.1840070213. [DOI] [PubMed] [Google Scholar]
  4. Levin S., Hahn T. Interferon system in acute viral hepatitis. Lancet. 1982 Mar 13;1(8272):592–594. doi: 10.1016/s0140-6736(82)91751-2. [DOI] [PubMed] [Google Scholar]
  5. Pedersen J. S., Toh B. H., Locarnini S. A., Gust I. D., Shyamala G. N. Autoantibody to intermediate filaments in viral hepatitis. Clin Immunol Immunopathol. 1981 Nov;21(2):154–161. doi: 10.1016/0090-1229(81)90204-x. [DOI] [PubMed] [Google Scholar]
  6. Pozzetto B., Mogensen K. E., Tovey M. G., Gresser I. Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J Infect Dis. 1984 Nov;150(5):707–713. doi: 10.1093/infdis/150.5.707. [DOI] [PubMed] [Google Scholar]
  7. Shiozawa S., Chihara K., Shiozawa K., Fujita T., Ikegami H., Koyama S., Kurimoto M. A sensitive radioimmunoassay for alpha-interferon: circulating alpha-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients. Clin Exp Immunol. 1986 Oct;66(1):77–87. [PMC free article] [PubMed] [Google Scholar]
  8. Steis R. G., Smith J. W., 2nd, Urba W. J., Clark J. W., Itri L. M., Evans L. M., Schoenberger C., Longo D. L. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med. 1988 Jun 2;318(22):1409–1413. doi: 10.1056/NEJM198806023182201. [DOI] [PubMed] [Google Scholar]
  9. Suit B. E., Axelrod D., Moutsopoulos H. M., Decker J. L., Hooks J. J. Detection of anti-interferon antibodies in systemic lupus erythematosus. Clin Exp Rheumatol. 1983 Apr-Jun;1(2):133–135. [PubMed] [Google Scholar]
  10. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Trown P. W., Kramer M. J., Dennin R. A., Jr, Connell E. V., Palleroni A. V., Quesada J., Gutterman J. U. Antibodies to human leucocyte interferons in cancer patients. Lancet. 1983 Jan 15;1(8316):81–84. doi: 10.1016/s0140-6736(83)91737-3. [DOI] [PubMed] [Google Scholar]
  12. von Wussow P., Freund M., Block B., Diedrich H., Poliwoda H., Deicher H. Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. Lancet. 1987 Sep 12;2(8559):635–636. doi: 10.1016/s0140-6736(87)93034-0. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES